No quarterly revenue total was found in BOUNDLESS BIO, INC.'s SEC filings.
Boundless Bio, Inc. (BOLD) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$21.0 million. As of Jun 30, 2026 it held $72.6 million in cash and investments and $0 in total debt.
Revenue
—
Net income
$-23.69M
-51.2% vs year-ago quarter
Operating cash flow
$-20.97M
-77.3% vs year-ago quarter
Free cash flow
$-21.01M
-76.9% vs year-ago quarter
EPS
$-1.06
-51.4% vs year-ago quarter
Dividend per share
None
Shares outstanding
22.75M
+1.6% vs year-ago quarter
Net cash
$72.63M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BOLD (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- La Jolla, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1782303
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$24.4M | -$14.5M | -$14.0M | -$15.1M | -$17.1M |
| Net income | -$23.7M | -$13.6M | -$12.9M | -$13.9M | -$15.7M |
| Diluted EPS | -$1.06 | -$0.60 | -$0.58 | -$0.62 | -$0.70 |
| Operating cash flow | -$21.0M | -$15.0M | -$10.1M | -$10.2M | -$11.8M |
| Free cash flow | -$21.0M | -$15.0M | -$10.5M | -$10.2M | -$11.9M |
| Total assets | $73.7M | $141.0M | $157.1M | $168.7M | $179.5M |
| Total liabilities | $7.8M | $54.6M | $58.4M | $58.6M | $56.8M |
| Stockholders' equity | $66.0M | $86.4M | $98.7M | $110.2M | $122.7M |
| Cash and investments | $72.6M | $92.8M | $107.6M | $117.6M | $127.1M |
| Total debt | $0 | $48.3M | $49.0M | $49.8M | $49.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement
|
Aug 28, 2026 | Aug 28, 2026 |
| 10-Q | Quarterly report | Aug 7, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, Exit or restructuring costs, Unregistered share sale, Change in control, Officer or director change, Regulation FD disclosure, Other events
|
Jun 23, 2026 | Jun 22, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 17, 2026 | Jun 15, 2026 |
| 10-Q | Quarterly report | May 8, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 8, 2026 | May 8, 2026 |
All 161 Boundless Bio, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.